Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are ...

Market volatility has not dissuaded some insiders from making big share purchases. The most notable transactions came from ...

Analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for Edgewise Therapeutics in a research note issued on Wednesday, April 2nd. Leerink Partnrs analyst J. Schwartz now anticipates that the ...

Piper Sandler reaffirmed their overweight rating on shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) in a research ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 15.24%, which has investors questioning if this is right time to ...

Edgewise Therapeutics (EWTX) stock drops 17% after Scotiabank downgrades rating and cuts price target to $14. Read more here.

Colorado-based Edgewise Therapeutics, a muscle disease-focused biopharma company, closed 23% lower after Wednesday’s trading.

As previously reported yesterday, Scotiabank downgraded Edgewise Therapeutics (EWTX) to Sector Perform from Outperform with a price target of ...

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has announced the pricing of its underwritten offering of $200 million, with each ...

Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13, raising $200 million.